Nektar Therapeutics
(NASDAQ : NKTR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading NKTR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.28%72.671.2%$696.83m
CELGCelgene Corporation
-4.70%111.871.3%$645.43m
AMGNAmgen Inc.
-3.40%140.171.0%$605.61m
BIIBBiogen Inc.
-2.33%284.381.2%$526.97m
REGNRegeneron Pharmaceuticals, Inc.
-2.85%358.453.6%$382.78m
ALXNAlexion Pharmaceuticals, Inc.
0.73%125.071.9%$363.71m
ILMNIllumina, Inc.
-3.51%121.963.0%$177.14m
VRTXVertex Pharmaceuticals Incorporated
-3.11%75.692.9%$164.83m
INCYIncyte Corporation
-3.79%103.152.4%$161.54m
TSROTESARO, Inc.
-2.60%136.2417.1%$156.34m
IONSIonis Pharmaceuticals, Inc.
-3.52%45.7810.0%$147.58m
EXELExelixis, Inc.
-9.21%16.576.4%$116.16m
BMRNBioMarin Pharmaceutical Inc.
-1.84%81.474.5%$114.14m
BLUEBluebird Bio, Inc.
-9.44%71.5023.3%$112.20m
AAgilent Technologies, Inc.
-0.07%44.811.6%$111.54m

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.